本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗，我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示，便表示您已接受我們的網站使用條款。 關閉
環境部為促進手機回收循環再利用，不斷呼籲企業及通路建立回收目標並提供回收誘因，傑昇通信也觀察到，透過手機舊換新活動來折抵新機價格，確實促使通路回收數量提高；傑昇通信統計門市4月份二手機回收數量，公布2024年四月二手機回收占比排行，以消費者來回收舊手機品牌來看，數量最多的前五大品牌依序分別是蘋果（56%）、三星（19%）、OPPO（8%）、ASUS（4%）及vivo（4%）。 根據環保署統計，近年台灣手機銷售量超過500萬支，但回收率只有12％，在環境部不斷呼籲通路業者相互配合，全台最大連鎖通訊門市─傑昇通信不只挑戰手機市場最低價，自從將「高價回收二手機」納入服務項目後，幫消費者一併處理汰換後的舊機回收量逐年攀升，加上祭出不少回收誘因，因此越來越多民眾願意將家中閒置舊機拿出來回收。 另一方面，疫情後全球通膨急遽，使得新機價格居高不下，因此每逢新機上市前後，也是舊機換新機的高峰；傑昇通信特地統計門市2024年4月二手機回收占比排行，iPhone的回收量占比56%幾乎過半，與安卓手機回收量比例懸殊，進一步看品牌前三名回收機型，回收最多的機型是iPhone 11（128GB），其次則為iPhone 12（128GB）及iPhone 13（128GB），都是以標準版iPhone為主，回收價格也是最高的。 傑昇通信分析，除了蘋果，三星也是通路的回收主力，但是品牌回收量占比僅19%，前三名回收最多的單機也是以A系列為主，以Galaxy A52s（6GB/128GB）回收數量最多，其次則是Galaxy A71及Galaxy A52s（8GB/256GB），回收價多落在2千元內；傑昇通信指出，三星銷售量體一直以A系列較多，而使用中低階機型的消費者，經常會用到無法使用才願意汰換新機，因此回收殘值偏低。 觀察4月二手機回收量占比排行，旗艦機回收價格都不錯，回收占比4%的華碩，以ZenFone 7（8GB/128GB）回收數量最多，其次則為電競手機ROG Phone 5（16GB/256GB）及ROG Phone 6（16GB/512GB），且以上市2年的ROG Phone 6（16GB/512GB）回收價最高；傑昇通信認為，兩大陣營用戶之所以會有如此差異的原因，主要在於安卓機型的回收價值遠不如iPhone高，導致大部分安卓用戶不願走回收這條路。 然而不管甚麼機型，透過排行榜實際回收價值來看，傑昇通信坦言，手機零件有許多化學元素，回收也可節能減碳，讓新機、舊機都能提高循環利用，只是越晚拿出來回收，二手機的殘值越低，甚至慘不忍睹；也提醒消費者，以往只有舊換新方案，今年開始各品牌新機上市時，還會加碼指定回收其他品牌機型，提供更多折扣，想要換機的消費者可以多留意。
ADELAIDE, South Australia, June 3, 2024 /PRNewswire/ -- BioCina Pty Ltd., a global end-to-end biologics Contract Development and Manufacturing Organization (CDMO), announced the exclusive rights to utilize CelluTx's Recombination Based Plasmid System (RBPS) technology with BioCina's CDMO clients. RBPS is a cutting-edge technology for minicircle DNA (mcDNA) production involving site-specific recombination within a bacterial host, to separate the minicircle containing the gene of interest from the rest of the plasmid backbone, including the antibiotic resistance genes and origins of replication. This new technology has several advantages over older mcDNA technologies, including process scalability, exceptionally high recombination efficiency, higher yields, simpler purification processes due to the clear separation of minicircles from miniplasmids, and the ability to produce larger minicircles that can accommodate complex gene cassettes. The streamlined structure of the mcDNA leads to enhanced and prolonged transgene expression and makes it less immunogenic and safer for in vivo use. These benefits make RBPS a promising approach for advancing mcDNA production and expanding its potential applications in cell and gene therapies and other advanced therapeutics. An example of such application, announced last year, is the cGMP program that BioCina is currently delivering for GenomeFrontier, in which the RBPS technology is key to the scale-up of GenomeFrontier's CAR-T product. BioCina's Chief Executive Officer, Mark W. Womack stated, "We are pleased to announce our partnership with CelluTx enabling BioCina to exclusively provide this innovative technology to our clients around the world. We have already witnessed great success in utilizing it within our client portfolio and eagerly anticipate advancing many other client programs with the technology." CelluTx's Chief Executive Officer, Maurits Geerlings said, "We are very pleased to engage with BioCina for the worldwide deployment of the RBPS minicircle DNA technology. BioCina has proven capabilities and the highest commitment to its customers, which has been fundamental to our partnering with BioCina." Womack added, "Additionally, Australia offers one of the most attractive Tax Incentives available globally (up to 48.5% cash refund), making it an ideal destination for biologics companies looking to invest in scaling-up and manufacturing their products." About BioCinaBioCina is a global end-to-end biologics Contract Development and Manufacturing Organisation (CDMO), offering highest-quality, cost-effective cell line, process, analytical and formulation development, and cGMP clinical & commercial manufacturing of the microbial, pDNA and mRNA modalities. BioCina's first facility in Adelaide, South Australia is a testament to the quality of its work. It has a rich history of developing and manufacturing both clinical and commercial drug substance, backed by most critical SME's with an average tenure of 15+ years at the site. BioCina boasts an elite quality record having successfully passed regulatory inspections by the US FDA, Health Canada, and EMA. It is licensed by the Australian TGA for cGMP manufacturing of bulk drug substance or active intermediates. Through a partnership with NovaCina, BioCina offers clients a highest-quality fill-and-finish solution. BioCina is proud to have clients globally, including U.S., Europe, and the Asia Pacific. Because BioCina is not a drug developer, it only serves clients' products. BioCina is establishing a second large-scale, high-capacity end-to-end mammalian and microbial facility in Australia, to be ready for client service in 2026. Australia offers one of the most attractive tax incentives available globally (up to 48.5% cash refund), making it an ideal destination for biologics companies looking to invest in scaling-up and manufacturing products. Learn more at https://biocina.com. About CelluTxCelluTx, LLC is a Wayne, PA-based biotech company supporting the cell & gene therapy community through the deployment of the RBPS minicircle DNA Technology invented by Dr. Peter Mayrhofer. The RBPS Technology is designed to provide manufacturing scalability and optimal purity for clinical-grade minicircle DNA. Being devoid of bacterial backbone components, the RBPS Technology provides for safer and more transfection-efficient DNA product, particularly important for CAR-TCR therapies. The RBPS Technology helps optimize various therapeutic application areas where DNA is a critical component, whether it is used as a direct therapeutic, therapeutic intermediate or source for other manufacturing processes. CelluTx has a strategic collaboration with Austria-based Supercoiled Genetics GmbH to support customers at preclinical stage research and development level using the RBPS Technology. Media Contactmedia@biocina.com
Innovative biotech company pioneers PSYLO-100X, a non-hallucinogenic neuroplastogen with promising therapeutic potential SAN DIEGO, June 3, 2024 /PRNewswire/ -- Psylo, a leading biotechnology company focused on the development of next-generation neuroplastogens, today announced at the BIO Conference in San Diego the successful first close toward an $8 million USD Series Seed financing. This funding will accelerate the advancement of PSYLO-100X, the company's flagship non-hallucinogenic 5-HT2A agonist, poised to revolutionize the treatment of depression and other mental health disorders. PSYLO-100X distinguishes itself from first-generation psychedelics by eliciting neuronal remodeling without causing hallucinatory effects. This breakthrough compound demonstrates antidepressant-like effects in vivo and promotes neuroplasticity in vitro, while notably avoiding activation at the 5-HT2B receptor—a critical safety feature due to the cardiotoxicity risk associated with activation of this receptor. "We are thrilled to announce this funding milestone at the BIO Conference," said Joshua Ismin, CEO of Psylo. "This capital raise underscores strong confidence in Psylo's unique translational approach and the therapeutic potential of our pipeline. Our platform has yielded a non-hallucinogenic candidate designed to be safely administered at home without clinical supervision, and serves to advance our mission to address the mental health crisis for a broader patient population." The Series Seed financing was led by Tenmile, a leading Health investor, with participation from Palo Santo, Focalpoint Ventures (formerly Empath Ventures), Mystic Ventures, and Gaingels. Dr. Steve Burnell, Managing Director of Tenmile, expressed enthusiasm for the investment: "We have been incredibly impressed with Psylo's progress and the innovative approach they are taking to address mental health disorders. We are pleased to be investing in Psylo and are confident in their ability to advance PSYLO-100X, which we believe has the potential to make a significant impact in the neuro space." Key Highlights of PSYLO-100X: Non-hallucinogenic: Unlike traditional psychedelics, PSYLO-100X has been designed to remove hallucinatory effects, making it a safer and more accessible treatment option. Partially selective 5-HT2A agonist: PSYLO-100X selectively targets the 5-HT2A receptor without activating the 5-HT2B receptor, reducing the risk of cardiotoxicity. Promotes neuroplasticity: Increases the complexity of neurons in cell culture, suggesting potential for long-term therapeutic benefits. Antidepressant effects: Demonstrative pro-cognitive effects in vivo, offering a promising new treatment for depression, anxiety, and other ruminative disorders. "After three years of rigorous drug-discovery, we're hugely encouraged by our progress," noted Dr. Samuel Banister, Chief Scientific Officer at Psylo. "PSYLO-100X is a non-tryptamine, non-phenethylamine compound with a hugely promising preclinical profile. We believe this novel approach marks a significant leap forward in developing safer, more effective treatments." Psylo plans to utilize the Series Seed funds to continue to invest in their drug discovery platform, and advance PSYLO-100X through IND enabling studies, with the goal of initiating first in human clinical trials in 2025. Founded in Australia, Psylo recently restructured to become a US Delaware C-corp in-line with the fundraise, and has established labs at the University of Colorado Boulder and the University of New South Wales in Sydney. For more information about Psylo and its groundbreaking work in neuroplastogens, visit www.psylo.bio About Psylo Psylo is a biotechnology company dedicated to developing next-generation neuroplastogens to treat mental health disorders. By leveraging cutting-edge science and innovative therapeutic approaches, Psylo aims to transform the mental health landscape and improve the lives of millions worldwide.
倫敦2024年5月31日 /美通社/ -- 中國柔性 OLED 製造商一直在迅速加強其技術並增加出貨量，這對 Samsung Display 的主導地位構成了重大威脅。2024 年上半年，中國可摺疊 OLED 的出貨量預計將達到 640 萬台，超過 Samsung Display 在韓國的 570 萬台。在此期間，根據 Omdia 的智能手機顯示情報服務，中國製造的可摺疊 OLED 預計將佔總摺疊 OLED 出貨份額的 53%。 摺疊式 OLED 顯示器出貨份額 2021 年 2024 年上半年 Samsung Display 及 Samsung Galaxy Fold 已被認為是摺疊智能手機市場的先驅，在技術準備和消費者偏好方面都遙遙領先。然而，Huawei、Honor、Oppo、Vivo、Xiaomi、Transsion、ZTE 及 Lenovo MOTO 等中國品牌正在推出新穎和先進的可摺疊產品來迅速追趕。這項發展對中國柔性 OLED 製造商在進一步提高他們在市場上的地位方面有很大的優勢。 中國可摺疊 OLED 製造商在可摺疊 OLED 顯示器技術方面取得了顯著進步，例如低溫多晶矽 (LTPO)、觸控薄膜封裝、無偏光片技術 (COE)、120Hz 的可變更刷新率 、峰值亮度、超薄摺疊玻璃以及減少摺疊褶痕。這些創新技術讓 Huawei、Honor、Lenovo MOTO、Oppo、Vivo、Xiaomi、Transsion 及 ZTE 等中國智能手機品牌及 OEM 成功設計出新型的可摺疊型號 ，而 Samsung Galaxy Fold 主要採用了 Samsung Display 的最新可摺疊技術。隨著中國品牌和 OEM 增加了可摺疊智能手機裝置的出貨量，中國 OLED 製造商的出貨量也在上升。 「長期以來，Samsung Display 一直是摺疊顯示技術的市場領導者，推動發展並維持高生產率。然而，自 2023 年以來，中國 OLED 製造商一直在逐步增加出貨量。尤其是中國的柔性 Gen6 製造廠，例如 BOE 的 B11、ChinaStar 的 T4、Visionox 的 V2 及 V3 等。受益於提高的收益率和不斷增長的客戶群，這些製造廠正在加強生產摺疊顯示器。」Omdia 顯示器實踐高級研究總監 David Hsieh 評論道。 Hsieh 補充：「可摺疊智能手機顯示器市場錄得了顯著的增長，2021 年達到 1070 萬台，2022 年 1660 萬台，2023 年 2180 萬台；我們的預測表明，該市場將會在 2024 年達到 3000 萬台。中國 OLED 製造商的策略以及中國智能手機品牌的擴展工作，預計將成為這一增長軌跡的關鍵驅動力。」 關於 Omdia Omdia，作為Informa Tech的一部分，是一家專注於科技行業的領先研究和諮詢集團。憑藉對科技市場的深入瞭解，結合切實可行的洞察力，Omdia將賦能企業做出明智的增長決策。要瞭解更多資訊，請訪問www.omdia.com。 Fasiha Khan: Fasiha.khan@omdia.com
HEIDELBERG, Germany, May 30, 2024 /PRNewswire/ -- Full-Life Technologies (Full-Life), a fully integrated global radiotherapeutics company, today announced it has received clearance of its Investigational New Drug (IND) Application from the U.S. Food and Drug Administration (FDA) for clinical trials of 225Ac-FL-020, its PSMA-targeted radiopharmaceutical for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The company plans to begin clinical studies in the U.S. and globally in 2024. 225Ac-FL-020 employs targeted alpha-radiotherapy designed to selectively attack cancer cells, reducing the damage to healthy tissues. In preclinical models, radiolabeled FL-020 displayed a very promising in vivo biodistribution profile, with high and sustained tumor uptake and fast systemic clearance. 225Ac-FL-020 exhibited robust anti-tumor activity in LNCaP xenograft mice, with a favorable safety profile. The upcoming Phase I clinical trial will evaluate the safety, tolerability, and anti-tumor activity of 225Ac-FL-020, and will lay the groundwork for further clinical development, aiming to establish 225Ac-FL-020 as a valuable therapeutic option for patients with mCRPC. "The IND application clearance is a significant regulatory milestone in our development plan for 225Ac-FL-020", said Steffen Heeger, M.D., M.Sc., Chief Medical Officer of Full-Life. "This important step underscores our overall commitment to the therapeutic potential of radiopharmaceuticals and once again highlights the value of the team´s effort, dedication, and cross-functional collaboration. We are excited to initiate the Phase I clinical program, which provides the first opportunity to gather human data on 225Ac-FL-020's safety and anti-tumor activity." About 225Ac-FL-020225Ac-FL-020 is a novel, potential best-in-class, next-generation PSMA-targeting radionuclide drug conjugate (RDC) that will enter global Ph1 clinical studies in 2024. Its targeting vector, FL-020, was discovered using Full-Life's proprietary UniRDC™ platform, which enables significant improvement of drug uptake in the tumor while maintaining fast systemic clearance. In pre-clinical models, 225Ac-FL-020 has demonstrated potent anti-tumor activity and a favorable safety profile. About Full-Life TechnologiesFull-Life Technologies ("Full-Life") is a fully integrated global radiotherapeutics company with operations in Belgium, Germany, and China. We aim to own the entire value chain for radiopharmaceutical research & development, production & commercialization in order to deliver clinical impact for patients. The Company plans to attack core issues affecting radiopharmaceuticals today through innovative research that targets the treatments of tomorrow. We are comprised of a team of fast-moving entrepreneurs and scientists with a demonstrated track record in the life sciences, as well as radioisotope research and clinical development.
LONDON, May 29, 2024 /PRNewswire/ -- China's flexible OLED makers have been rapidly advancing their technology and increasing their shipments posing a significant threat to Samsung Display's dominance. In the first half of 2024, China foldable OLED shipments are projected to reach 6.4 million units, surpassing Samsung Display's 5.7 million units in South Korea. According to Omdia's Smartphone Display Intelligence Service, China-made foldable OLEDs are expected to account for 53% of the total foldable OLED shipment share during this period. Foldable OLED display shipment share 2021 1H24 Samsung Display and Samsung Galaxy Fold have been recognized as pioneers in the foldable smartphone market, leading in both technology readiness and consumers' preference. However, Chinese brands such as Huawei, Honor, Oppo, Vivo, Xiaomi, Transsion, ZTE and Lenovo MOTO are quickly catching up by launching new, refreshed and advanced foldable products. This development is of great benefit to Chinese flexible OLED makers in boosting their position further in the market. China foldable OLED makers have made significant strides in progressing foldable OLED display technologies such as LTPO (Low Temperature Polysilicon Oxide), Touch on Thin Film Encapsulation, COE (Color Filter on Encapsulation) , variable refresh rate 120Hz, peak brightness, ultra-thin foldable glass, and reducing the folding crease. These innovations have led to successful designs in new foldable models from Chinese smartphone brands and OEMs like Huawei, Honor, Lenovo MOTO, Oppo, Vivo, Xiaomi, Transsion and ZTE, while Samsung Galaxy Fold is mainly incorporating the latest foldable technologies from Samsung Display. As Chinese brands and OEMs increase their foldable smartphone devices shipments, shipments from Chinese OLED makers' is also on the rise. "Samsung Display has long held the mantle of the market leader in foldable display technology driving development and maintaining high production yield rates. However, since 2023, Chinese OLED makers have been progressively increasing their shipment shares. Notably Chinese flexible Gen6 Fab such as BOE's B11, ChinaStar's T4, Visionox's V2 and V3 are ramping up production of foldable displays, benefiting from improved yield rates and a growing customer base," commented David Hsieh, Senior Research Director in Omdia's Displays practice. "The foldable smartphone display market witnessed remarkable growth reaching 10.7 million units in 2021, 16.6 million units in 2022, and 21.8 million units in 2023 with our projections indicating the market will reach 30 million units in 2024. The strategies of China's OLED makers alongside the expansion efforts of Chinese smartphone brands are expected to be key drivers of this growth trajectory," added Hsieh. ABOUT OMDIA Omdia, part of Informa Tech, is a technology research and advisory group. Our deep knowledge of tech markets combined with our actionable insights empower organizations to make smart growth decisions. Fasiha Khan: Fasiha.khan@omdia.com
A12 藝術空間
vivo
請先登入後才能發佈新聞。
還不是會員嗎？立即 加入台灣產經新聞網會員 ，使用免費新聞發佈服務。 （服務項目） （投稿規範）
